PARIS--(BUSINESS WIRE)--Regulatory News: ExonHit Therapeutics (Paris:ALEHT) today announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
